Showing 5051-5060 of 5621 results for "".
- Long-Term Pentosan Polysulfate Sodium Use Tied to Macular Diseasehttps://modernod.com/news/long-term-pentosan-polysulfate-sodium-use-tied-to-macular-disease/2477106/Use of the interstitial cystitis drug pentosan polysulfate sodium (PPS) was associated with a new diagnosis of macular disease at the 7-year follow-up in a large retrospective matched cohort study, according to a Reuters report. 
- Baring Private Equity Asia Agrees to Acquire Lumenishttps://modernod.com/news/baring-private-equity-asia-agrees-to-acquire-lumenis/2477103/Baring Private Equity Asia announced that its affiliated private equity funds have agreed to acquire Lumenis, a leading provider of specialty energy-based medical devices across the fields of aesthetics, urology, ophthalmology, ENT and gynecology from XIO. The transaction values Lumenis at an ent
- CovalentCareers Releases 2019 Optometrist Reporthttps://modernod.com/news/covalentcareers-releases-2019-optometrist-report/2477100/Career development company CovalentCareers has released its 2019 Optometrist Report, which is now available for free for eyecare professionals. Based on data collected from 1,181 optometrists, optometry studen
- FDA Approves First Contact Lens Indicated to Slow Progression of Myopia in Childrenhttps://modernod.com/news/first-contact-lens-for-childhood-myopia-coming-to-the-united-states-in-2020/2477098/The FDA approved the first contact lens indicated to slow the progression of myopia in children between the ages of 8 and 12 years old at the initiation of treatment. The MiSight contact lens made by CooperVision is a single use, disposable, soft contact lens that is discarded at the end of each
- Katena Announces the Acquisition of Micro Medical Instrumentshttps://modernod.com/news/katena-announces-the-acquisition-of-micro-medical-instruments/2477093/Katena Products announced the purchase of Micro Medical Instruments (MMI), a medical contract manufacturing service. Terms of the deal were not disclosed. “The acquisition of MMI, Inc. will strengthen Katena’s manufacturing capability,” Mark Fletcher, CEO of Katena Products, said i
- Iveric bio Initiating Second Pivotal Clinical Trial of Zimura in GA Secondary to Dry AMDhttps://modernod.com/news/iveric-bio-initiating-second-pivotal-clinical-trial-of-zimura-in-ga-with-1q-2020-targeted-for-first-patient-enrolled/2477090/Iveric bio provided further clinical details and its development strategy for Zimura (avacincaptad pegol), a novel complement C5 inhibitor, for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Based on the study design and the robustness of the rec
- Armenian EyeCare Project Surpasses Milestone of 10,000 Patients Screened Using Artificial Intelligence Eye Screening Technologyhttps://modernod.com/news/armenian-eyecare-project-surpasses-milestone-of-10000-patients-screened-using-artificial-intelligence-eye-screening-technology/2477088/On this World Diabetes Day, the Armenian EyeCare Project (AECP), a nonprofit organization dedicated to eliminating preventable blindness in Armenia, announced that it has surpassed the milestone of screening 10,000 patients for diabetic retinopathy (DR) throughout Armenia utilizing the state-of-a
- Envision Announces Dates, Calls for Submissions for 2020 Conferenceshttps://modernod.com/news/envision-announces-dates-calls-for-submissions-for-2020-conferences/2477082/Envision announced that it is now accepting submissions for clinical education and research presentations for its two annual conferences in 2020: Envision Conference West, April 3-4, UT Health San Antonio Department of Occupational Therapy in San Antonio, Texas; and Envision Conference East, Augu
- Novaliq and Jiangsu Hengrui Medicine Announce a Collaboration for Investigational NOV03 and CyclASol in Chinahttps://modernod.com/news/novaliq-and-jiangsu-hengrui-medicine-announce-a-strategic-collaboration-in-ophthalmology-for-the-eyesol-based-investigational-products-nov03-and-cyclasol-in-china/2477080/Novaliq and Jiangsu Hengrui Medicine, a biopharmaceutical company based in China, announced the closing of an exclusive license agreement to develop, manufacture and commercialize water-free drugs NOV03 and CyclASol for the treatment of dry eye disease in the People’s Republic of China (including
- Ocular Therapeutix Announces Strategic Update and Operational Restructuringhttps://modernod.com/news/ocular-therapeutix-announces-strategic-update-and-operational-restructuring/2477081/Ocular Therapeutix announced an operational restructuring plan that the company says is expected to result in an estimated $11 million in annualized savings through personnel reductions and approximately $14 million in one-time program deferrals. The company estimates that it will record costs as